Replies to post #6817 on Navidea Biopharmaceuticals Inc (NAVB)

[Cave In Temptor]

A few bits of positivism:
- 67% growth q/q.
- use increased by 120+ hospitals in q2 to 350.
- positive buzz: so much less painful to patients than sulfur colloid, easier on hospital scheduling and it seems less costly globally.

[diddobuyer]

I have been following this company for 4 years, the analysts have never gotten their price targets right once,none of them, so stop touting that as a reason to buy this stock. Not one of them had this right they all said 5-7 upon FDA approval and look what has happened. Those analyst estimates are worthless. Many also said 100 mill in revenues by 2014 and that was also dead wrong. The over estimated the market even with the 6 month CRL delay so stop touting their estimates as a reason to buy this stock, it is not a reason to buy unless you an ignoramus.